Image: ModernaTX, Inc., the primary operating subsidiary and official web domain of Moderna, Inc.

A new mRNA influenza vaccine from Moderna, approved by the U.S. Food and Drug Administration (FDA) on August 5, has already been linked to 78 reports of adverse events in a federal safety monitoring system.

MFLUSIVA is reportedly a vaccine for active immunization against influenza caused by virus subtypes A and B contained in the vaccine.

But does the vaccine present a greater threat than the influenza it aims to prevent? Reports filed in the Vaccine Adverse Event Reporting System (VAERS) through late October document instances of sudden mobility loss, partial vision impairment, cardiac arrhythmia, syncope, and hospitalization.

A recent Focal Points report highlighted several of these concerning entries from VAERS, which were also shared on X by Nicholas Hulscher, an Epidemiologist and Administrator at the McCullough Foundation.

 

BREAKING: Reports of serious injuries and disabilities with Moderna’s new mRNA flu shot have begun to FLOOD the CDC’s Vaccine Adverse Event Reporting System.

Among them are accounts of sudden inability to walk, partial vision loss, cardiac arrhythmias, fainting, and hospitalization.

This hazardous gene therapy should NEVER have been approved.

Here are some of the most concerning cases:

71-year-old woman: Reportedly lost the use of her legs following vaccination.

71-year-old man: Unable to stand or walk approximately 17 hours after vaccination. Remained on the floor for about an hour.

74-year-old woman: Partial vision loss in both eyes, severe headache, fever, and weakness.

78-year-old man: Severe tremors and involuntary movements affecting his arms and body.

74-year-old man: Severe dizziness, confusion, and difficulty walking steadily.

73-year-old man: Severe vertigo and vomiting, forcing him to stop approximately every 100 feet while walking home.

72-year-old man: Developed atrial fibrillation, subsequently confirmed by ECG.

71-year-old man: Collapsed after dizziness, visual disturbances, and breathing difficulty. Blood pressure fell to 72/46 mmHg.

58-year-old woman: Lost consciousness, experienced irregular heartbeats, breathing difficulties, and repeated near-fainting episodes.

69-year-old man: Reportedly fainted THREE TIMES, accompanied by chills, sweating, and dry heaving.

89-year-old woman: Fainted and fell inside a pharmacy shortly after vaccination. Transported to the emergency department.

Elderly patient: HOSPITALIZED with decreased oxygen saturation and fever.

76-year-old man: Hallucination-like episodes, fever, severe malaise, and disturbed sleep.

55-year-old man: Pronounced swelling of the upper lip.

61-year-old patient: Lost consciousness, experienced high fever for two days, and developed a headache.

56-year-old woman: Unable to get out of bed for 36 HOURS because of fever, widespread pain, fatigue, and dehydration.

50-year-old woman: Fever reaching 102.8°F and severe arm pain preventing her from raising her arms overhead.

These are among 78 VAERS reports involving mFLUSIVA in the October 30, 2026 data release.

VAERS only captures less than 1% of actual adverse events, according to the Harvard-Lazarus study.

Our peer-reviewed reanalysis of FDA clinical trial data had already identified 6 TIMES the risk of severe Grade 3 systemic reactions compared with conventional flu shots.

Thus, it’s no surprise that large numbers of serious injuries and disabilities have begun to pour in.

I call for IMMEDIATE MARKET REMOVAL of Moderna’s mFLUSIVA to protect innocent civilians from disability and death.

— Nicolas Hulscher, MPH (@NicHulscher) November 11, 2026

The Gateway Pundit spoke to Hulscher, author of the report and creator of the video. He quickly pointed out that “VAERS is widely understood to capture only a fraction of actual incidents,” referencing a Harvard-Lazarus study which estimated under one percent of incidents are actually reported.

“This underreporting,” he argued, “makes our foundation’s own peer-reviewed reanalysis of FDA clinical trial data all the more critical—it indicated the vaccine carries a risk of severe systemic reactions six times higher than that of conventional influenza vaccines.”

“In our study,” Hulscher stated, “risk-benefit projections suggested that for every hospitalization for influenza prevented by the mRNA vaccine relative to standard options, there were an estimated 3,798 adverse reactions, 278 severe events preventing normal activity, and two excess deaths from unexplained causes.”

According to him, these revelations stand in stark contrast to any initial assurances of safety and efficacy, raising fundamental questions about regulatory oversight and the adequacy of current pharmacovigilance systems in capturing true risk profiles for novel medical interventions.

“Given these preliminary findings,” Hulscher said, “The McCullough Foundation maintains its position that MFLUSIVA’s risk profile justifies its removal from the market.”

 

The post Moderna’s mRNA Flu Shot Linked to Surge in Severe Adverse Events, VAERS Data Shows appeared first on The Gateway Pundit.

Leave a Reply

Your email address will not be published. Required fields are marked *